Synergy of Polydopamine Nanovaccine and Endostar Alginate Hydrogel for Improving Antitumor Immune Responses Against Colon Tumor

Overview

Journal Int J Nanomedicine

Publisher Dove Medical Press

Specialty Biotechnology

Date 2022 Oct 17

PMID 36246936

Authors

Ying Yang

Ning Wang

Xinxin Tian

Xiaoli Wang

Jing Yang

XiGang Leng

Hailing Zhang

Affiliations

Soon will be listed here.

Abstract

Background: Tumor immunotherapy, a novel type of therapeutic treatment, has a wide range of applications with potentially prolonged benefits. However, current immunotherapy has a low overall response rate in treating a variety of tumors. Combination of immunotherapy with other therapies can improve the therapeutic response rates. The purpose of this work was to explore the potential of anti-angiogenic treatment in combination with tumor cell lysate loaded polydopamine nanoparticle vaccine as a therapeutic strategy for colon tumor.

Methods: We grafted tumor cell lysate onto polydopamine nanoparticles as nano-vaccine (TCLN) and fabricated alginate hydrogel loaded with Endostar (EH), then detected characteristics of EH and TCLN. We also estimated the cytotoxicity of EH/TCLN in vitro. In the tumor-bearing mouse model, we evaluated the antitumor effect of EH/TCLN treatment, and developed the animal survival study. After performing the EH/TCLN treatment, we also analyzed T cells and DCs using flow cytometry, and determined T cell responses and tumor microenvironmental cytokines. At last, we assessed the effect of the EH/TCLN treatment on anti-angiogenesis further.

Results: When applied in combination with TCLN in MC-38 tumor-bearing mice, EH/TCLN significantly suppressed tumor growth with more than half of the mice showing tumor regression. In addition, EH/TCLN treatment resulted in noticeable changes in the tumor microenvironment. As compared with the control group, EH/TCLN treatment led to significantly reduced tumor angiogenesis and expression of tumor microenvironment-related cytokines (TMCs), increased proportion of CD8 T cells in the spleen, lymph node and tumor, elevated activity of cytotoxic T lymphocytes (CTLs) and tumor cell apoptosis.

Conclusion: The present study demonstrated that the EH/TCLN treatment effectively created a favorable immune microenvironment for the induction of antitumor immunity and improved antitumor immune responses.

Citing Articles

Engineered nanoparticles for precise targeted drug delivery and enhanced therapeutic efficacy in cancer immunotherapy.

Peng X, Fang J, Lou C, Yang L, Shan S, Wang Z Acta Pharm Sin B. 2024; 14(8):3432-3456.

PMID: 39220871 PMC: 11365410. DOI: 10.1016/j.apsb.2024.05.010.

Cancer Immunotherapy with "Vascular-Immune" Crosstalk as Entry Point: Associated Mechanisms, Therapeutic Drugs and Nano-Delivery Systems.

Jiang Z, Fang Z, Hong D, Wang X Int J Nanomedicine. 2024; 19:7383-7398.

PMID: 39050878 PMC: 11268745. DOI: 10.2147/IJN.S467222.

Material matters: exploring the interplay between natural biomaterials and host immune system.

Tripathi A, Zaki M, Al-Hussain S, Dubey B, Singh P, Rind L Front Immunol. 2023; 14:1269960.

PMID: 37936689 PMC: 10627157. DOI: 10.3389/fimmu.2023.1269960.

References

de Palma M, Biziato D, Petrova T . Microenvironmental regulation of tumour angiogenesis. Nat Rev Cancer. 2017; 17(8):457-474. DOI: 10.1038/nrc.2017.51. View

Tugues S, Burkhard S, Ohs I, Vrohlings M, Nussbaum K, Vom Berg J . New insights into IL-12-mediated tumor suppression. Cell Death Differ. 2014; 22(2):237-46. PMC: 4291488. DOI: 10.1038/cdd.2014.134. View

Liu X, Nie W, Xie Q, Chen G, Li X, Jia Y . Endostatin reverses immunosuppression of the tumor microenvironment in lung carcinoma. Oncol Lett. 2018; 15(2):1874-1880. PMC: 5774419. DOI: 10.3892/ol.2017.7455. View

Zhang Y, Li X, Zhong N, Huang Y, He K, Ye X . Injectable in situ dual-crosslinking hyaluronic acid and sodium alginate based hydrogels for drug release. J Biomater Sci Polym Ed. 2019; 30(12):995-1007. DOI: 10.1080/09205063.2019.1618546. View

Wu J, Ding D, Ren G, Xu X, Yin X, Hu Y . Sustained delivery of endostatin improves the efficacy of therapy in Lewis lung cancer model. J Control Release. 2008; 134(2):91-7. DOI: 10.1016/j.jconrel.2008.11.004. View

Kathania M, Khare P, Zeng M, Cantarel B, Zhang H, Ueno H . Itch inhibits IL-17-mediated colon inflammation and tumorigenesis by ROR-γt ubiquitination. Nat Immunol. 2016; 17(8):997-1004. DOI: 10.1038/ni.3488. View

Wang X, Wang N, Yang Y, Wang X, Liang J, Tian X . Polydopamine nanoparticles carrying tumor cell lysate as a potential vaccine for colorectal cancer immunotherapy. Biomater Sci. 2019; 7(7):3062-3075. DOI: 10.1039/c9bm00010k. View

Hu X, Wu T, Qin X, Qi Y, Qiao Q, Yang C . Tumor Lysate-Loaded Lipid Hybrid Nanovaccine Collaborated with an Immune Checkpoint Antagonist for Combination Immunotherapy. Adv Healthc Mater. 2018; 8(1):e1800837. DOI: 10.1002/adhm.201800837. View

Schreiber R, Old L, Smyth M . Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011; 331(6024):1565-70. DOI: 10.1126/science.1203486. View

10.

Tartour E, Pere H, Maillere B, Terme M, Merillon N, Taieb J . Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy. Cancer Metastasis Rev. 2011; 30(1):83-95. DOI: 10.1007/s10555-011-9281-4. View

11.

Wang L, Yao B, Li Q, Mei K, Xu J, Li H . Gene therapy with recombinant adenovirus encoding endostatin encapsulated in cationic liposome in coxsackievirus and adenovirus receptor-deficient colon carcinoma murine models. Hum Gene Ther. 2011; 22(9):1061-9. DOI: 10.1089/hum.2011.014. View

12.

Goldberg M . Improving cancer immunotherapy through nanotechnology. Nat Rev Cancer. 2019; 19(10):587-602. DOI: 10.1038/s41568-019-0186-9. View

13.

Kisker O, Becker C, Prox D, Fannon M, Damato R, Flynn E . Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model. Cancer Res. 2001; 61(20):7669-74. View

14.

Wang H, Mooney D . Biomaterial-assisted targeted modulation of immune cells in cancer treatment. Nat Mater. 2018; 17(9):761-772. DOI: 10.1038/s41563-018-0147-9. View

15.

Xu Q, Gu J, Lv Y, Yuan J, Yang N, Chen J . Angiogenesis for tumor vascular normalization of Endostar on hepatoma 22 tumor-bearing mice is involved in the immune response. Oncol Lett. 2018; 15(3):3437-3446. PMC: 5795950. DOI: 10.3892/ol.2018.7734. View

16.

Wang J, Wang S, Ye T, Li F, Gao X, Wang Y . Choice of Nanovaccine Delivery Mode Has Profound Impacts on the Intralymph Node Spatiotemporal Distribution and Immunotherapy Efficacy. Adv Sci (Weinh). 2020; 7(19):2001108. PMC: 7539204. DOI: 10.1002/advs.202001108. View

17.

Sojka D, Fowell D . Regulatory T cells inhibit acute IFN-γ synthesis without blocking T-helper cell type 1 (Th1) differentiation via a compartmentalized requirement for IL-10. Proc Natl Acad Sci U S A. 2011; 108(45):18336-41. PMC: 3215041. DOI: 10.1073/pnas.1110566108. View

18.

Du R, Lu K, Petritsch C, Liu P, Ganss R, Passegue E . HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell. 2008; 13(3):206-20. PMC: 2643426. DOI: 10.1016/j.ccr.2008.01.034. View

19.

Huang K, Wu H, Lin H, Liang P, Chen P, Chen S . Combining antiangiogenic therapy with immunotherapy exerts better therapeutical effects on large tumors in a woodchuck hepatoma model. Proc Natl Acad Sci U S A. 2010; 107(33):14769-74. PMC: 2930482. DOI: 10.1073/pnas.1009534107. View

20.

Huang Y, Yang C, Wei P, Huynh T, Whang-Peng J, Meng T . Ovatodiolide suppresses colon tumorigenesis and prevents polarization of M2 tumor-associated macrophages through YAP oncogenic pathways. J Hematol Oncol. 2017; 10(1):60. PMC: 5329923. DOI: 10.1186/s13045-017-0421-3. View